Abstract
Summary
Contract manufacturing is a type of outsourcing in which a company enters into an agreement or legal agreement for a product, part or component with another manufacturing company, who then uses that agreement or legal settlement of the product in its production process. This involves the manufacture of biopharmaceutical molecules, proteins, nucleic acids, blood components and vaccines developed from biological sources. These companies specialize in the production of molecules and provide different types of services such as development processes, analysis, and quality control.
The global market for Biologics Contract Manufacturing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Biologics Contract Manufacturing include Lonza Group, Samsung Biologics Co., Ltd., Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Fujifilm Holding Corporation, AbbVie, Inc., Boehringer Ingelheim and Recipharm Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics Contract Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biologics Contract Manufacturing by region & country, by Type, and by Application.
The Biologics Contract Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics Contract Manufacturing.
Market Segmentation
By Company
Lonza Group
Samsung Biologics Co., Ltd.
Thermo Fisher Scientific, Inc.
Cambrex Corporation
Siegfried Holding AG
Fujifilm Holding Corporation
AbbVie, Inc.
Boehringer Ingelheim
Recipharm Pharmaceuticals
WuXi Biologics
Catalent, Inc.
Segment by Type:
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Molecular Therapy
Others
Segment by Application
Medical Company
Hospital
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biologics Contract Manufacturing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biologics Contract Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biologics Contract Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Biologics Contract Manufacturing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Biologics Contract Manufacturing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Biologics Contract Manufacturing include Lonza Group, Samsung Biologics Co., Ltd., Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Fujifilm Holding Corporation, AbbVie, Inc., Boehringer Ingelheim and Recipharm Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics Contract Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biologics Contract Manufacturing by region & country, by Type, and by Application.
The Biologics Contract Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics Contract Manufacturing.
Market Segmentation
By Company
Lonza Group
Samsung Biologics Co., Ltd.
Thermo Fisher Scientific, Inc.
Cambrex Corporation
Siegfried Holding AG
Fujifilm Holding Corporation
AbbVie, Inc.
Boehringer Ingelheim
Recipharm Pharmaceuticals
WuXi Biologics
Catalent, Inc.
Segment by Type:
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Molecular Therapy
Others
Segment by Application
Medical Company
Hospital
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biologics Contract Manufacturing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biologics Contract Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biologics Contract Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Biologics Contract Manufacturing Product Introduction
1.2 Global Biologics Contract Manufacturing Market Size Forecast
1.3 Biologics Contract Manufacturing Market Trends & Drivers
1.3.1 Biologics Contract Manufacturing Industry Trends
1.3.2 Biologics Contract Manufacturing Market Drivers & Opportunity
1.3.3 Biologics Contract Manufacturing Market Challenges
1.3.4 Biologics Contract Manufacturing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biologics Contract Manufacturing Players Revenue Ranking (2023)
2.2 Global Biologics Contract Manufacturing Revenue by Company (2019-2024)
2.3 Key Companies Biologics Contract Manufacturing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biologics Contract Manufacturing Product Offered
2.5 Key Companies Time to Begin Mass Production of Biologics Contract Manufacturing
2.6 Biologics Contract Manufacturing Market Competitive Analysis
2.6.1 Biologics Contract Manufacturing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biologics Contract Manufacturing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics Contract Manufacturing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Recombinant Proteins
3.1.3 Vaccines
3.1.4 Molecular Therapy
3.1.5 Others
3.2 Global Biologics Contract Manufacturing Sales Value by Type
3.2.1 Global Biologics Contract Manufacturing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biologics Contract Manufacturing Sales Value, by Type (2019-2030)
3.2.3 Global Biologics Contract Manufacturing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medical Company
4.1.2 Hospital
4.2 Global Biologics Contract Manufacturing Sales Value by Application
4.2.1 Global Biologics Contract Manufacturing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biologics Contract Manufacturing Sales Value, by Application (2019-2030)
4.2.3 Global Biologics Contract Manufacturing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biologics Contract Manufacturing Sales Value by Region
5.1.1 Global Biologics Contract Manufacturing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biologics Contract Manufacturing Sales Value by Region (2019-2024)
5.1.3 Global Biologics Contract Manufacturing Sales Value by Region (2025-2030)
5.1.4 Global Biologics Contract Manufacturing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biologics Contract Manufacturing Sales Value, 2019-2030
5.2.2 North America Biologics Contract Manufacturing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biologics Contract Manufacturing Sales Value, 2019-2030
5.3.2 Europe Biologics Contract Manufacturing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biologics Contract Manufacturing Sales Value, 2019-2030
5.4.2 Asia Pacific Biologics Contract Manufacturing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biologics Contract Manufacturing Sales Value, 2019-2030
5.5.2 South America Biologics Contract Manufacturing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biologics Contract Manufacturing Sales Value, 2019-2030
5.6.2 Middle East & Africa Biologics Contract Manufacturing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biologics Contract Manufacturing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biologics Contract Manufacturing Sales Value
6.3 United States
6.3.1 United States Biologics Contract Manufacturing Sales Value, 2019-2030
6.3.2 United States Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biologics Contract Manufacturing Sales Value, 2019-2030
6.4.2 Europe Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biologics Contract Manufacturing Sales Value, 2019-2030
6.5.2 China Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biologics Contract Manufacturing Sales Value, 2019-2030
6.6.2 Japan Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biologics Contract Manufacturing Sales Value, 2019-2030
6.7.2 South Korea Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biologics Contract Manufacturing Sales Value, 2019-2030
6.8.2 Southeast Asia Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biologics Contract Manufacturing Sales Value, 2019-2030
6.9.2 India Biologics Contract Manufacturing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biologics Contract Manufacturing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Lonza Group
7.1.1 Lonza Group Profile
7.1.2 Lonza Group Main Business
7.1.3 Lonza Group Biologics Contract Manufacturing Products, Services and Solutions
7.1.4 Lonza Group Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.1.5 Lonza Group Recent Developments
7.2 Samsung Biologics Co., Ltd.
7.2.1 Samsung Biologics Co., Ltd. Profile
7.2.2 Samsung Biologics Co., Ltd. Main Business
7.2.3 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Products, Services and Solutions
7.2.4 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.2.5 Samsung Biologics Co., Ltd. Recent Developments
7.3 Thermo Fisher Scientific, Inc.
7.3.1 Thermo Fisher Scientific, Inc. Profile
7.3.2 Thermo Fisher Scientific, Inc. Main Business
7.3.3 Thermo Fisher Scientific, Inc. Biologics Contract Manufacturing Products, Services and Solutions
7.3.4 Thermo Fisher Scientific, Inc. Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.3.5 Cambrex Corporation Recent Developments
7.4 Cambrex Corporation
7.4.1 Cambrex Corporation Profile
7.4.2 Cambrex Corporation Main Business
7.4.3 Cambrex Corporation Biologics Contract Manufacturing Products, Services and Solutions
7.4.4 Cambrex Corporation Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.4.5 Cambrex Corporation Recent Developments
7.5 Siegfried Holding AG
7.5.1 Siegfried Holding AG Profile
7.5.2 Siegfried Holding AG Main Business
7.5.3 Siegfried Holding AG Biologics Contract Manufacturing Products, Services and Solutions
7.5.4 Siegfried Holding AG Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.5.5 Siegfried Holding AG Recent Developments
7.6 Fujifilm Holding Corporation
7.6.1 Fujifilm Holding Corporation Profile
7.6.2 Fujifilm Holding Corporation Main Business
7.6.3 Fujifilm Holding Corporation Biologics Contract Manufacturing Products, Services and Solutions
7.6.4 Fujifilm Holding Corporation Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.6.5 Fujifilm Holding Corporation Recent Developments
7.7 AbbVie, Inc.
7.7.1 AbbVie, Inc. Profile
7.7.2 AbbVie, Inc. Main Business
7.7.3 AbbVie, Inc. Biologics Contract Manufacturing Products, Services and Solutions
7.7.4 AbbVie, Inc. Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.7.5 AbbVie, Inc. Recent Developments
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Profile
7.8.2 Boehringer Ingelheim Main Business
7.8.3 Boehringer Ingelheim Biologics Contract Manufacturing Products, Services and Solutions
7.8.4 Boehringer Ingelheim Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.8.5 Boehringer Ingelheim Recent Developments
7.9 Recipharm Pharmaceuticals
7.9.1 Recipharm Pharmaceuticals Profile
7.9.2 Recipharm Pharmaceuticals Main Business
7.9.3 Recipharm Pharmaceuticals Biologics Contract Manufacturing Products, Services and Solutions
7.9.4 Recipharm Pharmaceuticals Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.9.5 Recipharm Pharmaceuticals Recent Developments
7.10 WuXi Biologics
7.10.1 WuXi Biologics Profile
7.10.2 WuXi Biologics Main Business
7.10.3 WuXi Biologics Biologics Contract Manufacturing Products, Services and Solutions
7.10.4 WuXi Biologics Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.10.5 WuXi Biologics Recent Developments
7.11 Catalent, Inc.
7.11.1 Catalent, Inc. Profile
7.11.2 Catalent, Inc. Main Business
7.11.3 Catalent, Inc. Biologics Contract Manufacturing Products, Services and Solutions
7.11.4 Catalent, Inc. Biologics Contract Manufacturing Revenue (US$ Million) & (2019-2024)
7.11.5 Catalent, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Biologics Contract Manufacturing Industrial Chain
8.2 Biologics Contract Manufacturing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biologics Contract Manufacturing Sales Model
8.5.2 Sales Channel
8.5.3 Biologics Contract Manufacturing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer